[Diagnosis and Therapy of aplastic anemia - update 2021]. / Diagnostik und Therapie der aplastischen Anämie Update 2021.
Dtsch Med Wochenschr
; 146(7): 451-454, 2021 04.
Article
in De
| MEDLINE
| ID: mdl-33780990
ABSTRACT
The landscape of aplastic anemia (AA) is changing as new therapeutic options become available and sophistic diagnostics enable us to decipher various subgroups of bone marrow failure syndromes (BMFS) such as telomeropathies and other constitutional diseases with manifestations beyond childhood.This article briefly summarizes developments of the last few years with potential clinical impact and puts it into perspective. Focus is given to the growing list of inherited BMFS and the need to e.âg. screen patients at all ages for telomeropathies before initiation of treatment as part of routine evaluation of AA. The usage of next generation sequencing (NGS) to differentiate between AA and malignancies such as myelodysplatic syndrome (MDS) and the need to watch out for potential clonal evolution during and after treatment is also briefly discussed. Recent data on combinations of immunosuppressive therapy (IST) with thrombopoietin receptor agonists (TRA) for patients with severe AA as well as newer data with TRA mono-therapy for patients with moderate AA are presented. Finally the importance of supportive measures, structures and quality of life aspects are highlighted.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bone Marrow Failure Disorders
/
Anemia, Aplastic
Type of study:
Diagnostic_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
De
Journal:
Dtsch Med Wochenschr
Year:
2021
Document type:
Article
Publication country:
ALEMANHA
/
ALEMANIA
/
DE
/
DEUSTCHLAND
/
GERMANY